Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$8.28 and traded as low as C$7.80. Fennec Pharmaceuticals shares last traded at C$7.90, with a volume of 1,652 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Price Performance

The business has a 50-day moving average of C$8.28 and a two-hundred day moving average of C$7.65. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. The firm has a market cap of C$216.14 million, a P/E ratio of 79.00 and a beta of 0.25.

Fennec Pharmaceuticals (TSE:FRX) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported C($0.29) EPS for the quarter, missing analysts’ consensus estimates of C($0.19) by C($0.10). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. During the same quarter last year, the business posted ($0.09) EPS. On average, sell-side analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.6037736 earnings per share for the current fiscal year.

Insider Transactions at Fennec Pharmaceuticals

In related news, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were purchased at an average price of C$3.43 per share, for a total transaction of C$54,248.88. Also, Director Rostislav Christov Raykov sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of C$8.76, for a total value of C$87,552.00. In the last ninety days, insiders acquired 41,612 shares of company stock valued at $157,868. Corporate insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.